Drug intelligence / Profile preview

acetylkitasamycin

Development stage: Unknown
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Acetylkitasamycin is a macrolide antibiotic derivative of kitasamycin developed and marketed by ApicHope Pharmaceuticals. It is primarily indicated for the treatment of bacterial infections, particularly in pediatric populations. The drug functions by binding to the 50S subunit of the bacterial ribosome, which inhibits protein synthesis and halts bacterial growth. It is formulated as a dry suspension for oral administration and is part of ApicHope's portfolio of pediatric medications in China.

Other names: acetylkitasamycin for suspension乙酰吉他霉素干混悬剂

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on acetylkitasamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetylkitasamycin.

Explore the full profile